EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy

Carrie E Andrews, Jenny Zilberberg, Raul Perez-Olle, Mark A Exley, David W Andrews

Journal of Neuro-Oncology · 2023

DOI: 10.1007/s11060-023-04491-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuro-Oncology, 2023. Verfasst von Carrie E Andrews und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, 19107, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To date, immunotherapeutic approaches in glioblastoma (GBM) have had limited clinical efficacy as compared to other solid tumors. Here we explore autologous cell treatments that have the potential to circumvent treatment resistance to immunotherapy for GBM.

Methods

We performed literature review and assessed clinical outcomes in phase 1 safety trials as well as phase 2 and 3 autologously-derived vaccines for the treatment of newly-diagnosed GBM. In one recent review of over 3,000 neuro-oncology phase 2 and phase 3 clinical trials, most trials were nonblinded (92%), single group (65%), nonrandomized (51%) and almost half were GBM trials. Only 10% involved a biologic and only 2.2% involved a double-blind randomized trial design.

Results

With this comparative literature review we conclude that our autologous cell product is uniquely antigen-inclusive and antigen-agnostic with a promising safety profile as well as unexpected clinical efficacy in our published phase 1b trial. We have since designed a rigorous double-blinded add-on placebo-controlled trial involving our implantable biologic drug device. We conclude that IGV-001 provides a novel immunotherapy platform for historically intransigent ndGBM in this ongoing phase 2b trial (NCT04485949).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsCancer VaccinesHumansTreatment OutcomeImmunotherapyCraniotomyRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Brain tumorCancer vaccineGlioblastomaImmunotherapy

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
  • Imvax, Inc., Philadelphia, PA, 19602, USA.
  • Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, 19107, USA. d.andrews@imvax.com.
  • Imvax, Inc., Philadelphia, PA, 19602, USA. d.andrews@imvax.com.

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Andrews, C. E., Zilberberg, J., Perez-Olle, R., Exley, M. A., & Andrews, D. W. (2023). Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-023-04491-4

Vancouver

Andrews CE, Zilberberg J, Perez-Olle R, Exley MA, Andrews DW. Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy. Journal of Neuro-Oncology. 2023. doi:10.1007/s11060-023-04491-4

BibTeX
@article{Andrews2023,
  author = {Andrews, Carrie E and Zilberberg, Jenny and Perez-Olle, Raul and Exley, Mark A and Andrews, David W},
  title = {Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy},
  journal = {Journal of Neuro-Oncology},
  year = {2023},
  doi = {10.1007/s11060-023-04491-4}
}
Kostenlos starten →